| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Reactive oxygen species (ROS) are involved in the metastatic prostate cancer. To prevent metastatic prostate cancer, we developed polyetheylene glycol (PEG) modified platinum-gold alloy nanoparticles, which exhibited ROS-scavenging activities and high plasma retention after intravenous injection. The high plasma retention of nanoparticles with PEG modification has some advantages for the targeted delivery of nanoparticles to the prostate tumor through enhanced permeability and retention (EPR) effect. However, the cellular uptake by prostate cancer cells could be limited by steric hindrance of PEG after the delivery of nanoparticles. Therefore, to enhance the cellular uptake and efficacy of nanoparticles in prostate cancer cells, we developed a prostate cancer-specific cleavable PEG system using PSA-sensitive cleavable peptide. These technologies are promising approaches for preventing metastatic prostate cancer.
|
